



**Dementia: Big Problem**  
**Big data**  
**Big solution?**

# Big Problem

INFOGRAPHIC

## The global impact of dementia




Around the world, there will be 9.9 million new cases of dementia in 2015,


**one every 3 seconds**

46.8 million people worldwide are living with dementia in 2015.

This number will almost double every 20 years.



Much of the increase will take place in low and middle income countries (LMICs): in 2015, 58% of all people with dementia live in LMICs, rising to 63% in 2030 and 68% in 2050.




The total estimated worldwide cost of dementia in 2015 is US\$ 818 billion. By 2018, dementia will become a trillion dollar disease, rising to **US\$ 2 trillion by 2030**

If global dementia care were a country, it would be the

**18th largest economy**

in the world exceeding the market values of companies such as Apple and Google



(source: Forbee 2015 ranking).




This map shows the estimated number of people living with dementia in each world region in 2015.

We must now involve more countries and regions in the global action on dementia.


# Big Problem

Figure 2.4


**The growth in numbers of people with dementia (millions) in high income (HIC) and low and middle income countries (LMIC)**



# The precision medicine challenge




# The experimental medicine challenge



# Big Data: European EHR perspective

Country	Source (n)	Setting	Diagnosis	Cognition	Comorbidities	Medication	Care Quality	Imaging	Genetics	Health status	Lifestyle	Socio-econ
Denmark	Nat. patient registers (5.6M)	Hospital	✓		✓							
	50 linked clinical databases (5.6M)	Hospital	✓		✓							
France	Memento	Memory clinic	✓	✓	✓	✓		✓		✓		
Netherlands	IPCI (2M)	Primary care	✓		✓	✓				✓		
	Amsterdam Dementia cohort (4K)	Memory clinic	✓	✓		✓						
	Parelsnoer clinical cohort (1K)	Nat. memory clinic		✓	✓							
	ACTIFCare cohort (400)	Home living	✓	✓					✓		✓	✓
	Learn cohort (300)	Memory clinic	✓	✓	✓	✓		✓			✓	✓
Spain	SIDIAP (5.8M)	Primary care	✓		✓	✓				✓		✓
	ReDeGi register (6K)	Hospital	✓	✓	✓							
Sweden	LISA register (10M)	Insurance data										✓
	Nat. Patient registers (10M)	Hospital	✓									✓
	Social services register (10M)	Administrative										✓
	Tax Agency's register (10M)	Administrative										✓
	VEGA health care reg. (1.6M)	Regional reg.					✓					
	QRegPV (10M)	Primary care	✓				✓					
	National health care regs. (10M)	Administrative			✓					✓	✓	
	Military service register (7M)	Administrative	✓	✓	✓	✓		✓	✓	✓	✓	✓
	Gothenburg pop. studies (10K)	Population cohorts	✓	✓	✓	✓		✓	✓	✓	✓	✓
Women's cohort (400)	Population cohort											
UK	CPRD (5M)	Primary care	✓		✓	✓				✓		
	SAIL (3M)	National linkage	✓		✓	✓						✓
	UK CRIS (3M)	Mental health	✓		✓	✓						
	HSCIC (56M)	Hospital	✓		✓							
	SHIP (5.7M)	National linkage	✓	✓	✓	✓		✓	✓			✓
				✓	✓	✓						✓

# Age-specific incidence of dementia according to data source: The Million Women Study



# Danish National Patient Registry

**22 years (1994 - 2016)**

**7.1 million patients**

## Hospital data

- Diagnoses (ICD-10)
- Date of diagnose
- Type of encounter
- Hospital ID
- Ward ID




## Personal data

- Date of birth
- Gender
- Date of death
- Family




# The Complexity / Diversity problem: 171,607 Dementia diagnoses



# The Specificity Problem:

## Limitations of disease agnostic approaches



# Conclusion

## **Disease agnostic approaches deliver:**

- Too much diversity / complexity
- Data access remains difficult
- (Sample access almost impossible)
- Increasing data security requirements
- Complicated governance
- Bespoke data models



YOU TOLD US  
YOU MAKE DRILLS

# YOU DON'T

# YOU MAKE HOLES

# Next generation cohorts (population and clinical)

**Trends:**            **Constrained funding environment**  
                         **More targeted questions**  
                         **Greater added value**

**Response:**        **Cost-efficient technologies**  
                         **Purposive designs**  
                         **Consent for trials**

**For dementia:** **Dementia dedicated population and clinical cohorts**  
**Sensitive to early detection & disease progression**  
**Standard and efficient digital measures**

**Cognition**

**Function**

**Mood**

**Economic impact**

# Next generation cohorts

## **Purpose driven:**

Etiology vs. public health

## **Platform based:**

Integrated knowledge management

multi-modal data, standardisation, simplification

Economies of scale

Multiple studies from same informatics infrastructure

## **Technology led:**

Frequent, light touch digital phenotyping

Psychometrically efficient measures


Centralised linkage

Dedicated biosample collection and management

## **Infrastructure embedded:**

Education, work, health care

# Psychometric efficiency: Computer adaptive testing (EPQN –R)



# A Platform for the Remote Conduct of Gene-Environment Interaction Studies

John Gallacher<sup>1\*</sup>, Rory Collins<sup>2</sup>, Paul Elliott<sup>3</sup>, Stephen Palmer<sup>1</sup>, Paul Burton<sup>4</sup>, Clive Mitchell<sup>1</sup>, Gareth John<sup>5</sup>, Ronan Lyons<sup>6</sup>

Age	50+ years
Invitations:	15,000 (est. 10,000 connected)
Respondents:	663 (4.5% of 15k, 6% of 10k)
Complaints:	7
Follow-up rate:	99.9% linkage
Nested biosampling trial	
buccal same request	n=182 (136 samples received: 75%)
blood spot request	n=172 (19 samples received: 70%)

# Population sample: Representative or heterogenous?






Figure 1. Distribution of age and deprivation according to invitation and response.  
doi:10.1371/journal.pone.0054331.g001


Panel A: Mean Choice Reaction Time (mSec)




Panel C: Fluid Intelligence



Panel B: Stroop Interference effect (mSec)




Panel D: Working memory




**Figure 3. Distribution of cognitive performance according to web or clinic administration.**  
doi:10.1371/journal.pone.0054331.g003


### Panel A: Life Satisfaction



### Panel C: Self Esteem




### Panel B: Self Efficacy



**Figure 4. Distribution of well-being scores according to web or clinic administration.**

doi:10.1371/journal.pone.0054331.g004

# Near continuous cognitive testing



App-based

## Near-continuous population based testing (regulatory approved)

- app based      whenever
- fully automated      inexpensive
- population assessment      full distribution
- domain focussed      pathology specific
- engaging      incentivised return

# Dementias Platform UK


Integrating the research environment  
to accelerate the discovery  
of new drugs for dementia

**Rapid data access**




**Recruitment to trials**

**Resourcing multi-centres studies**


# DPUK Overview



# Technology Networks



# Integrating the environment



	Data status	Cohort	Institution	Access process	n	Total
1	Full data upload to portal	Airwave [10]	Imperial	Portal + Cohort	53,280	151,865
2		BRACE [11]	Bristol	Portal	2,000	
3		Cam-CAN [12]	Cambridge	Portal + Cohort	3,000	
4		CamPaIGN [13]	Cambridge	Portal	142	
5		CaPS [14]	Bristol	Portal + Cohort	2,512	
6		CFAS I [15]	Cambridge	Portal	18,005	
7		CFAS II [16]	Cambridge	Portal	7,524	
8		Cygnus [17]	Manchester	Portal	200	
9		DFP pilot [18]	Oxford	Portal	15	
10		ELSA [19]	UCL	Portal	11,391	
11		EPINEF [20]	Yonsei (RoK)	Portal	2,008	
12		Generation Scotland [21]	Edinburgh	Portal	23,960	
13		GERAD LOAD [22]	Cardiff	Portal	10,454	
14		GERAD EOAD [23]	Cardiff	Portal	4,397	
15		ICICLE-PD [24]	Newcastle	Portal	318	
16		NIMROD [25]	Newcastle	Portal	276	
17		OPDC Discovery [26]	Oxford	Portal	1,589	
18		SMC Amyloid [27]	SMC Seoul (RoK)	Portal	120	
19		TRACK-HD [28]	UCL	Portal	366	
20		Whitehall II [29]	UCL	Portal + Cohort	10,308	
21	Data upload per project	ALSPAC [30]	Bristol	Cohort	15,656	1,879,048
22		BDR [31]	Bristol	Portal	3,200	
23		DIAN [32]	UCL	Portal + Cohort	437	
24		EPIC Norfolk [33]	Cambridge	Portal	25,639	
25		GENFI [34]	UCL	Portal + Cohort	515	
26		Healthwise Wales [35]	Cardiff	Portal + Cohort	6,000	
27		LBC1936 [36]	Edinburgh	Portal + Cohort	1,091	
28		Million Women [37]	Oxford	Cohort	1,300,000	
29		NSHD [38]	UCL	Portal + Cohort	5,362	
30		PICNICS [39]	Cambridge	Portal	290	
31		Protect [40]	Exeter	Cohort	14,000	
32		SABRE [41]	UCL	Portal + Cohort	4,858	
33		UK Biobank [42]	Oxford	Cohort	502,000	
34	Meta-data only available	AMPLE [43]	Newcastle	Portal	80	255,907
35		CHARIOT [44]	Imperial	Portal + Cohort	24,509	
36		CMERC [45]	Yonsei (RoK)	Portal	3,000	
37		Delphic [46]	UCL	Cohort	2,000	
38		EXTEND [47]	Exeter	Portal + Cohort	10,000	
39		HKU-NCDC [48]	Hong Kong University	Portal	500	
40		KOGES [49]	Yonsei (RoK)	Portal	200,000	
41		LEWY-PRO [50]	Newcastle	Portal	100	
42		Memento [51]	Bordeaux (Fra)	Portal + Cohort	2,323	
43		NAMGARM-2 [52]	Gyeongsang (RoK)	Portal	1,000	
44		NICOLA [53]	Queen's Belfast	Portal	8,500	
45		PaMIR [54]	Nottingham	Cohort	400	
46		PREVENT [55]	Edinburgh	Portal + Cohort	750	
47	PRIME [56]	Queen's Belfast	Portal	2,745		

Cohort

Data type


BB02\_JOBTRVTYPE\_1\_0

Variable name

Array

Wave


# Clinical Studies Register Structure



**By end of the DPUK1 project - expect to have enlisted 3 cohorts, recruited 2,000-5,000 volunteers, and have started recruiting from the register for EM studies.**

# Multicentre experimental studies: EM Incubator

*Pre-competitive knowledge brokerage*



### Expertise

- Academic partners
- Industry partners

### Infrastructure

- Data portal
- Recruitment
- Imaging network
- Stem-cell network
- UK-DRI / HDR-UK /JDR

### Funding

- Match funding
- Seed-corn funding
- Joint projects

DPUK  
Science  
communities

**Experimental medicine portfolio**



# Dementias Platform<sup>UK</sup>

Medical Research Council

Araclon Biotech

GRIFOLS

SomaLogic

Imperial College  
London



Swansea University  
Prifysgol Abertawe



UNIVERSITY OF  
CAMBRIDGE



Johnson & Johnson

INNOVATION



THE UNIVERSITY  
of EDINBURGH



Newcastle  
University



MANCHESTER  
1824  
The University of Manchester



CARDIFF  
UNIVERSITY

PRIFYSGOL  
CAERDYDD

UNIVERSITY OF  
OXFORD



MedImmune

